BMS-986205 (Linrodostat) is a small molecule inhibitor of Indoleamine 2, 3 dioxygenase (IDO) that is currently being evaluated in clinical trials for the oral treatment of advanced cancer. Initially, there were concerns regarding possible toxicity following administration, since BMS-986205 undergoes metabolism to form 4-chloroaniline. However, it was later determined that the downstream metabolites of 4-chloroaniline might be a greater concern. To evaluate the potential toxicity of these metabolites, a sensitive LC-MS/MS analytical method was needed to quantify both the parent compound and multiple metabolites. This presented a challenge since the method required the analysis of multiple analytes while still retaining the analytical sensitivity required to support studies. By utilizing a multi-function analytical method, we were able to quantify the necessary analytes using a complex LC-MS/MS-based method including the application of both negative and positive electrospray ionization.

BMS-986205 (Linrodostat) 是一种吲哚胺 2, 3 双加氧酶 (IDO) 的小分子抑制剂，目前正在临床试验中对晚期癌症的口服治疗进行评估。最初，有人担心给药后可能的毒性，因为 BMS-986205 会代谢形成 4-氯苯胺。然而，后来确定 4-氯苯胺的下游代谢物可能是一个更大的问题。为了评估这些代谢物的潜在毒性，需要一种灵敏的 LC-MS/MS 分析方法来量化母体化合物和多种代谢物。这提出了一个挑战，因为该方法需要分析多种分析物，同时仍保持支持研究所需的分析灵敏度。通过利用多功能分析方法，